Malignant pleural mesothelioma is a rare and aggressive cancer that develops in the tissue lining the lungs and chest wall, most commonly linked to past exposure to asbestos. While this disease cannot be cured in most cases, a combination of surgery, chemotherapy, radiation therapy, and newer immunotherapy approaches can help control symptoms, slow disease progression, and potentially extend life, offering patients valuable time and improved quality of life during their journey.

Understanding Treatment Goals and the Path Forward

When someone receives a diagnosis of malignant pleural mesothelioma, understanding what treatment can realistically achieve becomes essential. The main goals of treating this disease focus on controlling symptoms like chest pain and breathing difficulties, slowing down how fast the cancer grows, and helping patients maintain the best possible quality of life for as long as possible. Because pleural mesothelioma is usually discovered at a more advanced stage, completely removing all cancer is often not possible. However, this does not mean that treatment has nothing to offer.

Treatment decisions depend heavily on several factors unique to each patient. The stage of the disease at diagnosis plays a crucial role—early-stage mesothelioma caught before it spreads widely offers more treatment options than cancer that has already moved to other parts of the body. The specific type of cells making up the tumor also matters significantly. Doctors classify pleural mesothelioma into three cell types: epithelioid (the most common, making up 60-80% of cases and generally responding better to treatment), sarcomatoid (the rarest and most aggressive, accounting for about 10% of cases), and biphasic (a mix of both cell types, representing 10-15% of cases).^[1]

Patient characteristics such as age, overall fitness level, and the presence of other health conditions heavily influence which treatments doctors can safely recommend. A younger, healthier person might be able to tolerate aggressive surgery combined with chemotherapy, while someone with other serious health problems might benefit more from gentler approaches focused on symptom relief. The performance status—essentially how well someone can carry out daily activities—serves as a key indicator that medical teams use when planning treatment strategies.^[3]

Medical societies and cancer treatment organizations have developed standard treatment protocols based on years of research and clinical experience. These established approaches represent what doctors know works reasonably well for most patients. At the same time, researchers continue testing new therapies in clinical trials, exploring innovative molecules and treatment combinations that might offer better results than what is currently available. This means patients often have the option to receive either proven standard treatments or to participate in studies investigating promising new approaches.

Standard Treatment Approaches

Standard treatment for malignant pleural mesothelioma typically involves one or more of three main approaches: surgery, chemotherapy, and radiation therapy. Which combination works best depends on the stage of disease and the patient’s ability to tolerate aggressive treatment.

Surgical Options

Surgery is not a common treatment for pleural mesothelioma because completely removing all cancer cells proves extremely difficult given how the disease spreads along the thin lining of the chest cavity. However, for patients diagnosed at an early stage who are otherwise healthy and fit, surgery may offer the chance to remove as much tumor tissue as possible. The goal is either to potentially extend life or to control symptoms more effectively.^[13]

Two main types of surgery exist for pleural mesothelioma. Extrapleural pneumonectomy is the more extensive operation, involving removal of the entire lung on the affected side along with the pleural lining, the diaphragm, and the lining of the heart sac. This is a major operation with significant risks and requires patients to be in excellent health beforehand. Pleurectomy with decortication is a less radical approach that removes the pleural lining and visible tumor deposits while preserving the lung itself. This operation generally causes less stress on the body and allows more patients to recover well enough to receive additional treatments afterward.^[8]

Some surgeons perform debulking surgery, which aims to remove as much visible cancer as possible without attempting to get every last cell. This approach can help relieve symptoms like difficulty breathing and chest pain by reducing the tumor burden, even when cure is not possible. After surgery, patients typically need several weeks to recover before they can begin chemotherapy or radiation therapy. The decision about which type of surgery, if any, requires careful discussion between the patient and surgical team, weighing potential benefits against significant risks including infection, bleeding, blood clots, and breathing complications.^[13]

Chemotherapy as a Foundation

Chemotherapy uses powerful drugs to kill cancer cells or slow their growth throughout the body. For pleural mesothelioma, chemotherapy serves as a cornerstone of treatment, either given alone for patients who cannot undergo surgery, or combined with surgery and possibly radiation in patients with earlier-stage disease.

The standard chemotherapy combination for pleural mesothelioma consists of two drugs: pemetrexed and cisplatin. Pemetrexed works by interfering with how cancer cells make DNA and RNA, the building blocks they need to divide and grow. Cisplatin damages cancer cell DNA directly, preventing cells from repairing themselves and causing them to die. These drugs work better together than either one alone. In a major clinical study, patients who received both drugs together lived an average of 12.1 months compared to 9.3 months for those receiving only cisplatin, representing a significant improvement.^[17]

Chemotherapy for mesothelioma is typically given in cycles, with treatment days followed by rest periods to allow the body to recover. A common schedule involves receiving the drugs on day one of a 21-day cycle, then repeating this pattern for several months. Patients usually receive chemotherapy through an intravenous line in a treatment center or hospital. The total duration of chemotherapy typically spans four to six cycles, though this can be adjusted based on how well the cancer responds and what side effects develop.

Like all chemotherapy drugs, pemetrexed and cisplatin cause side effects. Common problems include nausea and vomiting, which can usually be controlled with anti-nausea medications. Fatigue is extremely common and can affect daily activities significantly. Both drugs can lower blood cell counts, increasing risks of infection, anemia, and bleeding problems. Pemetrexed can cause skin rashes and mouth sores. Cisplatin may damage kidneys, so patients need extra fluids and careful monitoring. It can also cause hearing loss and numbness or tingling in hands and feet (neuropathy). To reduce some side effects of pemetrexed, doctors prescribe vitamin supplements—specifically folic acid and vitamin B12—which help protect normal cells while still allowing the drug to attack cancer cells.^[13]

Radiation Therapy’s Role

Radiation therapy uses high-energy beams, similar to X-rays but much stronger, to damage cancer cell DNA and kill tumors. For pleural mesothelioma, radiation serves several purposes. After surgery, radiation may be directed at the surgical area to kill any remaining cancer cells that were too small to see or impossible to remove completely. This is called adjuvant radiation therapy.^[13]

More commonly, radiation treats symptoms in patients with advanced disease. When tumors grow large, they can press on nerves, blood vessels, and airways, causing severe chest pain, difficulty breathing, and coughing. Precisely targeted radiation can shrink these tumors, relieving pressure and improving symptoms even when it cannot cure the disease. Radiation can also treat areas where the cancer has spread through the chest wall, causing painful lumps under the skin.

Radiation therapy for mesothelioma typically occurs five days per week for several weeks. Each treatment session lasts only a few minutes, though setup and positioning take longer. The radiation itself is painless, but side effects develop over time. The most common problems include fatigue, which worsens as treatment continues, and skin changes in the treated area that resemble sunburn. Radiation to the chest can irritate the esophagus, causing difficulty or pain when swallowing. It may also inflame lung tissue, leading to cough and shortness of breath. Most side effects gradually improve after treatment ends, though some lung scarring may be permanent.

Multimodal Treatment Strategies

For selected patients with early-stage disease, doctors often recommend combining surgery, chemotherapy, and radiation—an approach called multimodality therapy or trimodality therapy. The idea is that each treatment attacks the cancer in different ways, potentially achieving better control than any single approach alone. A typical sequence might involve chemotherapy first to shrink the tumor, followed by surgery to remove as much cancer as possible, and then radiation to kill any remaining cells.^[19]

This aggressive approach requires patients to be relatively young, in good overall health, and highly motivated, as it demands months of difficult treatment with significant side effects. However, observational studies suggest that carefully selected patients who complete all three treatments may live longer than those receiving less intensive care. The challenge lies in determining which patients will benefit enough to justify the rigors of multimodality therapy versus those who would fare better with less aggressive approaches focused on quality of life.

Treatment Approaches in Clinical Trials

Because standard treatments for pleural mesothelioma offer limited benefit, with most patients living only 12-21 months even with treatment, researchers actively investigate new therapies in clinical trials. These studies test promising drugs and approaches that might work better than current options.

Immunotherapy: Harnessing the Body’s Defenses

One of the most exciting recent developments in mesothelioma treatment involves immunotherapy, a type of treatment that helps the patient’s own immune system recognize and attack cancer cells. Cancer cells normally find ways to hide from immune system surveillance or to turn off immune responses. Immunotherapy drugs remove these brakes, allowing immune cells to find and destroy tumors.

The most important breakthrough came with a combination of two immunotherapy drugs: nivolumab and ipilimumab. These drugs belong to a class called checkpoint inhibitors because they block molecular checkpoints that cancer cells use to evade immune attack. Nivolumab blocks a checkpoint called PD-1, while ipilimumab blocks another called CTLA-4. Using both drugs together appears more effective than either alone.

In a major clinical trial called CheckMate-743, researchers compared nivolumab plus ipilimumab directly against standard chemotherapy (pemetrexed plus cisplatin) in patients with previously untreated, unresectable pleural mesothelioma. The results showed that patients receiving the immunotherapy combination lived significantly longer. Median survival was 18.1 months with immunotherapy versus 14.1 months with chemotherapy. Even more impressively, 23% of patients receiving immunotherapy were still alive three years later, compared to only 15% of those who received chemotherapy. Among patients whose tumors responded to immunotherapy, 28% still had ongoing responses three years later, while none of the chemotherapy responders maintained their response that long.^[17]

Based on these results, the U.S. Food and Drug Administration (FDA) approved nivolumab combined with ipilimumab as a first-line treatment for unresectable malignant pleural mesothelioma in 2020. This means it can be used as the initial treatment rather than waiting until after chemotherapy fails. The approval represented a major advance, giving patients a new option that works differently than chemotherapy and may help some people live substantially longer.^[17]

Another immunotherapy drug, pembrolizumab, which also blocks the PD-1 checkpoint, has shown promise in clinical trials for mesothelioma patients. Some patients experience significant tumor shrinkage and prolonged disease control with pembrolizumab, either alone or in combination with chemotherapy. Research continues to determine which patients benefit most from immunotherapy and whether combining these drugs with chemotherapy or other treatments might work even better.^[17]

Immunotherapy side effects differ from chemotherapy because they result from an overactive immune system rather than directly poisoning cells. Common problems include fatigue, skin rashes, diarrhea, and inflammation of various organs. Sometimes the activated immune system attacks normal tissues, causing conditions like colitis (inflamed colon), hepatitis (inflamed liver), or pneumonitis (inflamed lungs). While these immune-related side effects can be serious, they often respond well to medications that calm down the immune system, such as corticosteroids. Close monitoring allows doctors to catch and treat these problems early.

Targeted Therapy: Precision Approaches

Targeted therapy refers to drugs designed to attack specific molecular abnormalities found in cancer cells while sparing normal cells. Unlike chemotherapy, which affects all rapidly dividing cells, targeted drugs aim at particular proteins or pathways that cancer cells depend on for growth and survival.

For mesothelioma, researchers have identified several molecular targets of interest. Some tumors have abnormalities in genes like BAP1 (BRCA1-associated protein 1), which normally helps suppress tumor formation. When this gene is mutated, cells lose an important brake on their growth. Scientists are developing drugs that might exploit these specific vulnerabilities, though most remain experimental.^[3]

Clinical trials are testing various targeted agents in mesothelioma. Some drugs target growth factor receptors on cancer cell surfaces, blocking signals that tell cells to divide. Others interfere with blood vessel formation (angiogenesis), cutting off the tumor’s blood supply. Still others target pathways inside cells that control survival and death. While none has yet proven as effective as immunotherapy, research continues to identify which molecular characteristics predict response to specific targeted drugs.

Gene Therapy and Other Innovative Approaches

Gene therapy represents a highly experimental approach that involves introducing genetic material into cancer cells or surrounding tissues to fight the disease. Some strategies aim to restore normal tumor suppressor genes that have been lost or damaged in mesothelioma cells. Others introduce genes that make cancer cells more visible to the immune system or more vulnerable to chemotherapy. While still in early-phase clinical trials, gene therapy offers theoretical advantages for cancers like mesothelioma where conventional treatments have limited success.

Researchers are also investigating novel ways to deliver cancer-fighting agents directly into the chest cavity. Photodynamic therapy uses light-activated drugs that preferentially accumulate in cancer cells. During surgery, doctors inject the drug, then expose the chest cavity to specific wavelengths of light that activate the drug, causing cancer cells to die. Intrapleural therapy involves putting chemotherapy or immunotherapy drugs directly into the space between the lung lining and chest wall, achieving high local drug concentrations while minimizing whole-body side effects.

Understanding Clinical Trial Phases

Clinical trials proceed through three main phases, each answering different questions. Phase I trials test a new treatment in a small number of people (typically 15-30 patients) for the first time. The main goal is determining safe doses and identifying side effects. Researchers start with very low doses and gradually increase them, watching carefully for problems. Phase I trials don’t primarily aim to shrink tumors, though researchers measure this if it happens.

Phase II trials involve more patients (often 30-100) and focus on whether the treatment actually works against the cancer. Researchers measure how often tumors shrink, how long patients live, and how quality of life is affected. They also continue monitoring for side effects. If a Phase II trial shows promising results, the treatment moves to Phase III.

Phase III trials directly compare the new treatment against current standard therapy in large groups of patients (often several hundred). Half the patients receive the new treatment while the other half gets standard care, with assignment determined randomly. These trials definitively establish whether the new treatment works better, worse, or the same as existing options. Only treatments that prove superior or equivalent with fewer side effects in Phase III trials typically gain approval from regulatory agencies like the FDA.

Participating in clinical trials gives mesothelioma patients access to promising new treatments before they become widely available. Patients receive close monitoring and expert care from specialized teams. However, clinical trial participation also involves uncertainty—the new treatment might not work as well as hoped, and side effects may be unpredictable. Additionally, some trials use placebos (inactive substances) or randomly assign patients to standard versus experimental treatment, meaning patients don’t always get to choose which they receive.

Many mesothelioma clinical trials are conducted at major cancer centers in the United States, Europe, and other developed countries. Eligibility criteria typically include having a confirmed mesothelioma diagnosis, adequate organ function, and good enough health to tolerate experimental treatment. Previous treatment history matters too—some trials accept only newly diagnosed patients who haven’t received any treatment yet, while others specifically enroll people whose disease has progressed despite standard therapy.

Palliative and Supportive Care

Palliative care focuses on relieving symptoms and improving quality of life rather than trying to cure the cancer. This type of care is appropriate for all mesothelioma patients, not just those with advanced disease or those who have stopped cancer-directed treatment. Palliative approaches can begin at diagnosis and continue alongside chemotherapy, surgery, or other treatments.

Managing chest pain represents a major palliative care priority in pleural mesothelioma. The cancer growing along the pleural lining often causes severe, persistent pain that interferes with breathing, sleeping, and daily activities. Pain management may involve oral medications including non-steroidal anti-inflammatory drugs, opioids like morphine or oxycodone, and adjuvant medications such as gabapentin that help with nerve-related pain. For severe pain, doctors might recommend nerve blocks—injections that temporarily interrupt pain signals from specific areas of the chest wall.

Breathlessness is another distressing symptom. Beyond treatments that shrink tumors, palliative approaches include draining fluid that accumulates between the lung and chest wall (a procedure called thoracentesis), supplemental oxygen, medications that reduce the sensation of air hunger, and breathing techniques taught by respiratory therapists. Some patients benefit from a procedure called pleurodesis, where doctors introduce a substance into the chest cavity that causes the lung lining to stick to the chest wall, preventing fluid from reaccumulating.^[13]

Other supportive care needs include nutritional counseling (many patients lose significant weight), physical therapy to maintain strength and mobility, psychological support for anxiety and depression, and practical assistance with daily tasks. Social workers help navigate insurance issues, arrange transportation to appointments, and connect patients with community resources. Palliative care teams work alongside oncologists, surgeons, and other specialists to address the whole person rather than just the disease.

Most Common Treatment Methods

• Chemotherapy
  • Combination of pemetrexed and cisplatin represents the standard first-line chemotherapy regimen for malignant pleural mesothelioma
  • Pemetrexed interferes with cancer cell DNA and RNA production while cisplatin damages DNA directly
  • Typically administered intravenously on day one of a 21-day cycle, repeated for four to six cycles
  • Median survival of 12.1 months with combination therapy versus 9.3 months with cisplatin alone
  • Common side effects include nausea, fatigue, low blood counts, kidney problems, neuropathy, and mouth sores
  • Vitamin supplementation with folic acid and vitamin B12 reduces side effects while maintaining effectiveness
• Immunotherapy
  • Nivolumab plus ipilimumab approved by FDA in 2020 as first-line treatment for unresectable malignant pleural mesothelioma
  • Checkpoint inhibitors that remove brakes on the immune system, allowing it to attack cancer cells
  • CheckMate-743 trial showed median survival of 18.1 months versus 14.1 months with chemotherapy
  • Three-year survival rate of 23% with immunotherapy compared to 15% with chemotherapy
  • Particularly effective in patients with non-epithelioid histology
  • Pembrolizumab also shows promise in clinical trials for mesothelioma
  • Side effects result from overactive immune system and may include fatigue, rashes, diarrhea, and inflammation of organs
• Surgery
  • Extrapleural pneumonectomy removes entire lung, pleural lining, diaphragm, and heart sac lining—most radical option
  • Pleurectomy with decortication removes pleural lining and visible tumors while preserving the lung
  • Debulking surgery removes as much visible cancer as possible to relieve symptoms
  • Surgery limited to early-stage patients who are otherwise healthy and fit
  • Often combined with chemotherapy and/or radiation in multimodality treatment approaches
  • Significant risks include infection, bleeding, blood clots, and breathing complications
• Radiation Therapy
  • Uses high-energy beams to damage cancer cell DNA and kill tumors
  • Adjuvant radiation given after surgery to kill remaining microscopic cancer cells
  • Palliative radiation shrinks tumors to relieve chest pain, breathing difficulty, and coughing
  • Typically administered five days per week for several weeks
  • Common side effects include fatigue, skin changes resembling sunburn, difficulty swallowing, and lung inflammation
• Multimodality Therapy
  • Combines surgery, chemotherapy, and radiation for carefully selected early-stage patients
  • Common sequence involves chemotherapy to shrink tumors, surgery to remove cancer, then radiation to kill remaining cells
  • Requires months of difficult treatment with significant side effects
  • Observational studies suggest selected patients may live longer than with single-modality approaches
  • Reserved for relatively young, healthy patients with good performance status
• Targeted Therapy
  • Drugs designed to attack specific molecular abnormalities in cancer cells
  • Some agents target growth factor receptors on cell surfaces
  • Others interfere with blood vessel formation to cut off tumor blood supply
  • Investigational approaches target pathways inside cells controlling survival and death
  • Most targeted therapies for mesothelioma remain experimental in clinical trials
• Palliative and Supportive Care
  • Thoracentesis drains fluid accumulation between lung and chest wall to improve breathing
  • Pleurodesis procedure prevents fluid reaccumulation by causing lung lining to stick to chest wall
  • Pain management with medications including NSAIDs, opioids, and adjuvant drugs like gabapentin
  • Nerve blocks provide temporary interruption of pain signals from chest wall
  • Supplemental oxygen and breathing techniques help manage breathlessness
  • Nutritional counseling, physical therapy, psychological support, and social work services address whole-person needs